On Friday, Organon & Co (NYSE: OGN) was -2.83% drop from the session before settling in for the closing price of $15.56. A 52-week range for OGN has been $10.84 – $23.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -7.62% over the past five years. When this article was written, the company’s average yearly earnings per share was at -0.39%. With a float of $256.98 million, this company’s outstanding shares have now reached $257.54 million.
Let’s look at the performance matrix of the company that is accounted for 10000 employees. In terms of profitability, gross margin is 58.26%, operating margin of 23.44%, and the pretax margin is 12.2%.
Organon & Co (OGN) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Organon & Co stocks. The insider ownership of Organon & Co is 0.22%, while institutional ownership is 81.23%. The most recent insider transaction that took place on Feb 22 ’24, was worth 49,939. In this transaction Gen. Counsel & Corp. Secy. of this company bought 2,720 shares at a rate of $18.36, taking the stock ownership to the 15,181 shares.
Organon & Co (OGN) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.39% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.83% during the next five years compared to -14.04% drop over the previous five years of trading.
Organon & Co (NYSE: OGN) Trading Performance Indicators
You can see what Organon & Co (OGN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.59. Likewise, its price to free cash flow for the trailing twelve months is 5.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 5.04, a number that is poised to hit 0.93 in the next quarter and is forecasted to reach 4.24 in one year’s time.
Technical Analysis of Organon & Co (OGN)
Organon & Co (NYSE: OGN) saw its 5-day average volume 2.2 million, a negative change from its year-to-date volume of 2.26 million. As of the previous 9 days, the stock’s Stochastic %D was 30.14%. Additionally, its Average True Range was 0.52.
During the past 100 days, Organon & Co’s (OGN) raw stochastic average was set at 8.43%, which indicates a significant decrease from 38.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.47% in the past 14 days, which was higher than the 36.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.86, while its 200-day Moving Average is $19.17. Nevertheless, the first resistance level for the watch stands at $15.56 in the near term. At $16.00, the stock is likely to face the second major resistance level. The third major resistance level sits at $16.25. If the price goes on to break the first support level at $14.87, it is likely to go to the next support level at $14.62. Assuming the price breaks the second support level, the third support level stands at $14.18.
Organon & Co (NYSE: OGN) Key Stats
There are 257,539K outstanding shares of the company, which has a market capitalization of 3.78 billion. As of now, sales total 6,263 M while income totals 1,023 M. Its latest quarter income was 1,582 M while its last quarter net income were 359,000 K.
